Towards prediction of HCV therapy efficiency

DOI10.1080/17486700903170712MaRDI QIDQ612807zbMATH OpenOpenAlexWikidataFDO

Authors Szymon Wasik, Paulina Jackowiak, Jacek B. Krawczyk, Pawel Kedziora, Piotr Formanowicz, Marek Figlerowicz, Jacek Blazewicz

Publication date 30 December 2010

Published in Computational \& Mathematical Methods in Medicine (Search for Journal in Brave)

Full work available at URL https://eudml.org/doc/229647

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Review text

Summary: We investigate a correlation between the genetic diversity of hepatitis C virus populations and the level of viral RNA accumulation in patient blood. Genetic diversity is defined as the mean Hamming distance between all pairs of virus RNA sequences representing the population. We have found that a low Hamming distance (i.e., low genetic diversity) correlates with a high RNA level; symmetrically, high diversity corresponds to a low RNA level. We contend that the obtained correlation strength justifies the use of the viral RNA level as a measure enabling prediction of efficiency of an established therapy. We also propose that patient qualification for therapy, based on viral RNA level, improves its efficiency.

Recommendations

• Machine learning for mathematical models of HCV kinetics during antiviral therapy
• Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy
• Dynamics of hepatitis C under optimal therapy and sampling based analysis
• Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin
• Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor
• Dynamics of hepatitis C viral load with optimal control treatment strategy
• Feasibility of parameter estimation in hepatitis C viral dynamics models
• Modelling hepatotoxicity and antiretroviral therapeutic effect in HIV/HBV coinfection
• Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis

Cited in

(3)

• Machine learning for mathematical models of HCV kinetics during antiviral therapy
• ModeLang: a new approach for experts-friendly viral infections modeling
• Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis

This page was built for publication: Towards prediction of HCV therapy efficiency

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q612807)